Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Danielle Hammond, MD
Advertisement
Articles by Danielle Hammond, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
2
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to TER-2013 for Advanced Breast Cancer
5